Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024

Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets

Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death

Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer

Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis

Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg

The product will be launched in March 2024

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies

The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies

Pharmatech Associates adds Dr. Praveen Tyle to Board of Trustees

Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure

Abbott India MD Vivek Kamath resigns

His resignation would be effective from March 18, 2024

AstraZeneca Pharma appoints Venkat Natarajan as Lead - Market Access

Currently, Venkat is Lead – Market Access, India at Pfizer

Zydus appoints Punit Patel as President and CEO, Americas

Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace